Participant flow15

How many started, completed or left each group, period by period.

1 to 15 of 15

Period	Milestone	Group	Participants
Overall Study	STARTED	Gemcitabine (G) Plus (+) Erlotinib (E): Rash ≥ Grade 2	106
Overall Study	STARTED	G+E Standard Dose: Rash Grade Less Than (<) 2	75
Overall Study	STARTED	G+E Escalating Dose: Rash Grade < 2	71
Overall Study	STARTED	G+E: No Rash Non-Eligibl	179
Overall Study	STARTED	G+E: Early Drop Out	36
Overall Study	COMPLETED	Gemcitabine (G) Plus (+) Erlotinib (E): Rash ≥ Grade 2	0
Overall Study	COMPLETED	G+E Standard Dose: Rash Grade Less Than (<) 2	0
Overall Study	COMPLETED	G+E Escalating Dose: Rash Grade < 2	0
Overall Study	COMPLETED	G+E: No Rash Non-Eligibl	0
Overall Study	COMPLETED	G+E: Early Drop Out	0
Overall Study	NOT COMPLETED	Gemcitabine (G) Plus (+) Erlotinib (E): Rash ≥ Grade 2	106
Overall Study	NOT COMPLETED	G+E Standard Dose: Rash Grade Less Than (<) 2	75
Overall Study	NOT COMPLETED	G+E Escalating Dose: Rash Grade < 2	71
Overall Study	NOT COMPLETED	G+E: No Rash Non-Eligibl	179
Overall Study	NOT COMPLETED	G+E: Early Drop Out	36

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00652366/flow